Prof. Dr. med. Jürgen Siebler

Professur für Hepatologie

Endoscopic recanalization of complete esophageal obstruction (2021) Vitali F, Naegel A, Pfeifer L, Goetz M, Neurath M, Rath T, Siebler J Journal article The Ominous Ouzo Party - A Case Series of Four Patients with Accidental Alkali Ingestion (2021) Vetter M, Rath T, Siebler J, Waldner M, Neurath M, Pfeifer L Journal article Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy (2021) Dietz J, Di Maio VC, de Salazar A, Merino D, Vermehren J, Paolucci S, Kremer A, et al. Journal article Safety analysis of the run-in phase (1st and 2nd cohort) of the IMMUNIB trial (AIO-HEP-0218/ass) - An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced stage HCC (2020) Vogel A, Mueller DW, De Toni E, Siegler GM, Lindig U, Mueller T, Schultheiss M, et al. Conference contribution Efficiency and Toxicity of Lenvatinib in Advanced HCC in Later Treatment Lines (2020) Jefremow A, Wiesmüller M, Rouse RA, Dietrich P, Kremer A, Waldner M, Neurath M, Siebler J Conference contribution Beyond the border: The use of lenvatinib in advanced hepatocellular carcinoma after different treatment lines: A retrospective analysis (2020) Jefremow A, Wiesmüller M, Rouse RA, Dietrich P, Kremer A, Waldner M, Neurath M, Siebler J Journal article Primary aortoduodenal fistula - Overlooked because of guidelines? (2020) Wiesmüller F, Neufert C, Croner R, Lang W, Grützmann R, Siebler J Journal article How Much Liver Tissue Is Required for Sufficient Histological Staging in Patients with Primary Biliary Cholangitis? (2020) Vetter M, Kremer A, Agaimy A, Pfeifer L, Neurath M, Zopf S, Siebler J Journal article Correction to: Influence of cancer and acute inflammatory disease on taste perception: a clinical pilot study (Supportive Care in Cancer, (2019), 27, 4, (1579), 10.1007/s00520-019-4642-6) (2020) Schalk P, Kohl M, Herrmann HJ, Schwappacher R, Rimmele M, Büttner A, Neurath M, et al. Journal article, Erratum A Phase 2 Study of Galunisertib (TGF-beta 1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (2019) Kelley RK, Gane E, Assenat E, Galle PR, Merle P, Hourmand IO, Cleverly A, et al. Journal article